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1 Substantial progress in the treatment of CHB has been made in the past two decades with the approval of interferon-(IFN-) based and nucleoside/nucleotide-based therapies. Although these two classes of agents have revolutionized the management of CHB, each has limitations. 2,3 Pegylated interferon-alpha (PEG-IFN-α) represents a finite treatment course, but is poorly tolerated and only elicits a sustained clinical response in a subset of patients. In contrast, the current nucleoside/nucleotides of choice (tenofovir disoproxil fumarate [tenofovir DF] and entecavir) represent safe, well-tolerated, highly-effective and durable on-treatment therapies. However, although nucleoside/nucleotide therapies significantly improve clinical end points, they generally require chronic administration to maintain viral suppression and benefit. Overall, the ability to "cure" HBV infection (with cure being defined as the loss of both HBV DNA and HBV surface antigen [HBsAg] plus seroconversion to anti-HBsAg antibody-positive, and maintenance of these end points after the cessation of therapy) presents a formidable challenge that is not adequately met by current therapies. A long-term study of tenofovir DF in HBV e antigen-(HBeAg-) positive CHB patients indicated that 5 years of therapy led to HBsAg loss in 10% of patients and full HBsAg seroconversion in 8% of patients. 4 Similarly, HBsAg loss was observed in 8% of HBeAg-positive patients treated with PEG-IFN-α for 1 year and followed for 3 additional years (HBsAg loss in 8% of patients 4 years after treatment initiation).
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This review will focus on new approaches for the treatment of CHB. New therapeutic targets and approaches can be divided into two main categories: (1) therapies that target the virus either directly or by targeting host factors required by the virus, and (2) therapies targeting the host innate or adaptive immune response. Before discussing new targets, it is helpful to review the replication cycle of HBV and the challenges it presents.
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Abstract
Chronic hepatitis B virus (CHB) is managed effectively with either nucleoside/nucleotide-based or interferon-based therapies. However, most patients receiving these therapies do not establish long-term, durable control of infection after treatment withdrawal. In particular, rates of hepatitis B surface-antigen loss and seroconversion to antisurface-antigen antibody are very low. Thus, novel therapies and treatment modalities are necessary to achieve either elimination of the virus from the liver or durable immune control of hepatitis B virus (HBV) infection in the absence of chronic therapy ("functional cure"). Here the authors review new targets and approaches for treating CHB. These approaches can be divided into two broad categories-those targeting the virus or host factors required by the virus and those targeting the innate or adaptive immune systems. Unfortunately, although a variety of promising strategies have been identified and several new approaches have achieved preclinical validation, relatively few novel drug candidates are in active clinical studies to treat CHB. Thus, functional cure of CHB infection remains an important therapeutic challenge.
The HBV Viral Lifecycle
The viral lifecycle is summarized in ►Fig. 1 and the reader is referred to reviews of HBV molecular virology for further details. 6, 7 
Approaches Targeting the Viral Lifecycle
New approaches targeting the virus directly or through host factors required by the virus are reviewed below and are presented sequentially according to the processes outlined in ►Fig. 1.
Viral Entry
The HBV entry process has historically been poorly understood due to the lack of robust in vitro infection systems. To date, limited HBV infection has only been supported in primary human or primary tupaia (tree shrew) hepatocytes and in the well-differentiated human hepatic cell line HepaRG. Using these systems, a series of peptide inhibitors derived from the large surface antigen of HBV were identified to inhibit HBV infection with nanomolar potency. 9 Not only can these peptides prevent in vitro infection of both HBV and HDV, but they are also effective in small animal models of infection after subcutaneous administration. 14 The compounds were identified through a cellbased high throughput screen and neither the mechanism nor the target for these compounds is currently known. A distinct approach to directly target cccDNA is the use of zinc-finger nucleases (ZFNs). ZFNs combine a nonspecific restriction enzyme domain with zinc-finger motifs that introduce sequence specificity. Although this approach is at an early stage of investigation, in vitro data indicate that ZFNs are able to cleave HBV DNA in hepatoma cells. 15 In addition, although cleaved target DNA can be repaired, this process often introduces mutations or deletions; mutation of HBV DNA was also observed during in vitro analyses. Because the HBV genome is compact and encodes multiple overlapping reading frames, it may be highly susceptible to inactivation by mutation. However, although the concept of specifically inactivating HBV DNA by cleavage and/or mutation is attractive, this approach will face the clinical challenges of preferentially delivering ZFNs to the liver; it also has the potential for off-target cleavage. Currently, adeno-associated viral vectors are being explored for ZFN delivery.
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Viral Transcription and mRNA Stability
Although it would be ideal to eradicate cccDNA from infected cells, another approach is to functionally inactivate cccDNA by either preventing transcription or degrading viral mRNA. cccDNA transcription can be blocked using zinc-finger proteins (ZFPs), in this case devoid of restriction nuclease domains. ZFPs can selectively recognize specific HBV target sequences with nanomolar affinity, and after binding, block the binding of transcription factors to cccDNA and/or hinder RNA polymerase read-through transcription. Proof of concept has been established in vitro using duck HBV (DHBV) and in cell lines with stable integrations of the X gene.
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Another approach to prevent transcription of cccDNA is to functionally "silence" it epigenetically. Recent results suggest that inactivation of cccDNA through epigenetic modifications represents an important mechanism of action for IFN-α. 19 Specifically, experiments in both cell culture and HBV-infected uPA-SCID mice transplanted with human hepatocytes indicated that HBV mRNA levels are markedly reduced by IFN-α at time points when cccDNA is not substantially affected. Furthermore, reductions in viral mRNA correlated with reductions in acetylated histones bound to cccDNA. Epigenetic regulation of cccDNA therefore represents a novel opportunity for modulation of cccDNA function. Although promising, a conceptual challenge for this approach is selectivity, as inhibition or activation of host epigenetic regulators may also modulate host gene transcription.
As an alternative to interfering with transcription from cccDNA, viral mRNA can be targeted directly by antisense oligonucleotides, ribozymes, or RNA interference (RNAi). HBV presents an ideal target for these technologies because all viral transcripts overlap in the 3′ region and are coterminal. By targeting the 3′ region of HBV mRNAs, the production of all HBV proteins could conceivably be blocked with a single RNA therapeutic molecule. There is in vitro proof of concept that hammerhead and hairpin ribozymes, as well as antisense oligonucleotides reduce HBV transcript levels in cell culture models. [20] [21] [22] However, few recent reports in ribozyme and antisense areas exist. In contrast, more progress has been made using RNAi. Multiple investigators have demonstrated that viral mRNA can be potently knocked down by RNAi, not only in cell culture, but also in small animal models of HBV. [23] [24] [25] However, although the potential to knock down viral proteins using RNA targeting approaches is tantalizing scientifically, significant challenges remain in the area of drug delivery. Nevertheless, multiple RNAi-based therapeutics have moved into the clinic for other indications; therefore, this approach could be considered for HBV.
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Viral Assembly
As indicated above, HBV genome replication takes place exclusively within nucleocapsids; therefore, dysregulation of capsid assembly will effectively block viral replication. glucose residues on glycosylated proteins (including HBsAg) and inhibiting host α-glucosidases. More recently, a class of triazolopyrimidines that inhibit HBsAg secretion was identified through a high throughput screening effort. 43, 44 The prototype "hit," HBF-0259, inhibited the accumulation of all three forms of HBsAg (large, middle, and small) in the media of HBV-expressing cell lines with an EC 50 of 1.5 µM. The mechanism of action remains to be determined, but appears to be distinct from that of the glucovirs.
Immunotherapeutic Strategies
Viruses that establish chronic infection employ a wide variety of strategies to avoid sterilizing immunity. With regard to HBV, evasion of innate immunity may contribute to the development of persistence, while a profoundly dysfunctional T-cell response is likely a key factor in the maintenance of chronicity. 45 Accordingly, over the past 20 years multiple immunotherapeutic strategies have been evaluated in CHB patients with the goal of reconstituting effective antiviral control. Initial proof-of-concept was demonstrated by resolution of CHB in the recipient of a bone marrow transplant from a donor with immunity to HBV. 46 In line with studies linking HBV persistence to a defect in adaptive immunity, 45 these early transplantation studies suggested that restoration of HBV-specific T-cell immunity can clear persistent infection. 47 Unfortunately, therapeutic translation of this knowledge has proven difficult. Indeed, a variety of therapeutic vaccination trials have yielded disappointing results and efforts to boost antiviral immunity with recombinant cytokines have also been largely unsuccessful. Accordingly, an urgent need remains to develop new immunotherapeutics to improve the rate of functional cure. Fortunately, recent advances in our understanding of the nature of immune dysfunction in chronic viral infections are leading to novel immune-based strategies to treat CHB. These approaches are briefly described below.
IFN Therapy
Currently, the only approved widely immunotherapeutic agent for the treatment of CHB patients is IFN-α (pegylated or nonpegylated). Despite more than 20 years of clinical use, the mechanism(s) by which IFN-α controls HBV replication are not completely understood. This remains an important goal because mechanistic understanding of IFN-α activity could drive rational design of novel immunotherapeutic strategies. It is therefore noteworthy that recent studies have shed new light on PEG-IFN-α treatment response. Most importantly, it was determined that PEG-IFN-α does not improve peripheral HBV-specific T-cell responses, and that virologic response may instead be related to activation of an NK cell subset. 48, 49 In addition, as discussed above, IFN-α inhibition of cccDNA transcription may also be an important mechanism of viral control.
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The importance of the direct antiviral response to IFN-α is in line with the therapeutic activity of IFN-λ which, by virtue of a restricted receptor expression pattern, presumably lacks many of the immunomodulatory functions (and associated toxicities) of IFN-α. 50, 51 An interim analysis of a phase 2 clinical study with PEG-IFN-λ1a (BMS-914143) revealed that this agent displayed at least comparable efficacy to PEG-IFN-α through 24 weeks of treatment, with a superior safety profile in most respects. 52 Because these data indicate that direct activation of hepatocytes by IFNs can induce a robust virologic response, targeted delivery of IFN-α to the liver may also be a useful therapeutic strategy.
53
Cytokine Therapeutics
Elegant studies in the LCMV mouse model have highlighted the potential of interleukin-7 (IL-7) and IL-21 for the treatment of chronic viral diseases. [54] [55] [56] [57] [58] Furthermore, IL-21 has been shown to play a key role in the age-dependent response to HBV in a transgenic mouse model, 59 although defective IL-21-producing T-cells have not been observed in young CHB patients. 60 Both rIL-7 and rIL-21 are in clinical development.
Although rIL-21 (BMS-982470) has so far only been tested in cancer patients, 61 rIL-7 (CYT107) is currently being evaluated in a phase 1/2a trial in CHB patients in combination with nucleoside/nucleotides (tenofovir DF or entecavir) and vaccination (GenHevac). 62 Encouragingly, rIL-7 has been well tolerated in early-phase clinical studies in cancer and human immunodeficiency virus (HIV) patients; 62 therefore, data from CHB patients are eagerly awaited.
Toll-Like Receptor (TLR) Agonists
Toll-like receptors are pattern-recognition receptors (PRRs) that recognize a variety of broadly conserved pathogenassociated molecular patterns (PAMPs). Pharmaceutical activation of TLRs is an attractive approach for the treatment of CHB because agonism of these receptors triggers innate immune responses and also stimulates adaptive immunity. This approach is supported by the demonstration that TLR activation can suppress hepadnavirus replication in vitro and in animal models. 63 Most notably, the small molecule oral TLR7 agonist GS-9620 demonstrated S-antigen loss and seroconversion in the woodchuck model of CHB 64 and sustained reduction of viremia and antigenemia in chronically infected chimpanzees. 65 GS-9620 is currently in phase 1b studies in treatment-naïve patients as well as in patients virologically suppressed with tenofovir DF.
Restoring HBV-Specific T-Cell Immunity
It is broadly accepted that clearance of acute HBV infection requires a vigorous, multispecific CD8 þ cytotoxic T-cell response, whereas persistent infection is associated with a limited and dysfunctional T-cell response. 66 Although the failure of nucleoside/nucleotides to typically achieve durable HBV suppression is likely related to the lack of sustained recovery of virus-specific T-cell function, 67 a recent study demonstrated that the HBV-specific T-cell response can in fact be restored (at least after in vitro expansion) in those select patients that do achieve HBsAg loss and seroconversion upon therapy. 68 This suggests that T-cell dysfunction during CHB is reversible; therefore, therapeutic strategies to restore effective antiviral T-cell response should be considered. 
Blocking Suppressive Cytokines and Regulatory T-Cells in the Liver
In addition to reducing the profound antigen load in HBV patients (discussed above), successful boosting of antiviral Tcell immunity may also benefit from modulation of suppressive cytokines in the liver microenvironment. Both IL-10 and TGF-β can contribute to the tolerogenic properties of the liver and blocking these cytokines can improve antiviral T and/or NK cell function. [79] [80] [81] [82] Various inhibitors of TGF-β are currently in preclinical and clinical development. 83 Although somewhat controversial, several studies have indicated that regulatory T-cells (Tregs) may also play a role in the inhibition of HBV-specific T-cell function. 84 Pharmaceutically, Tregs could be depleted and reprogrammed with a CD25-blocking monoclonal antibody such as daclizumab 85 or inhibited by TLR activation. 86 Therapeutic inhibition of TGF-β or Tregs has not been clinically validated in CHB patients, nor did these approaches induce a virologic response in chronically infected woodchucks when combined with IL-12 treatment.
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Conclusions and Perspectives for New Therapies
Approved therapies, particularly tenofovir DF and entecavir are able to manage disease in the majority of CHB patients, although the rate of functional cure (HBsAg loss and seroconversion) with these agents is low. Thus, there is an urgent need to develop novel therapeutics to achieve a functional cure, ideally with finite courses of therapy. Strategically, any new approaches based on targeting the virus, either directly or by inhibiting a host factor required for infection, will need to establish that target inhibition ultimately translates into improved HBsAg seroconversion. For example, simply blocking viral replication, even by a mechanism other than nucleoside/nucleotides, is unlikely to cure infection unless it impacts the cccDNA reservoir or fosters an enhanced immune response capable of controlling viral replication. Directly targeting cccDNA is an attractive strategy, although as a nucleic acid, cccDNA represents a challenge for conventional drug discovery. Approaches such as zincfinger nucleases and modulation of epigenetic regulators face a challenge to establish selectivity. Instead, approaches such as blocking antigen secretion or directly targeting viral RNA are more likely to be technically feasible in the near term. It is also hoped that the recent discovery of the HBV entry receptor will open new avenues to drug discovery by enabling more relevant in vitro models for virus replication and host response.
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The natural resolution of CHB in a small percentage of patients annually highlights the potential of host immunity to affect sustained viral control. Although immunotherapeutic approaches have been largely unsuccessful to date, our growing understanding of the immune defects in CHB are enabling the development of new strategies. PEG-IFN-λ1a and the TLR7 agonist GS-9620 represent promising immunotherapeutic approaches; hopefully, additional immune-based agents will soon follow these into the clinic. Although there is cause for optimism with new immune-based approaches, it is important to recognize the challenges of safely activating the immune system. The high safety bar for new CHB therapies may impede the development of immunotherapeutic approaches (e.g., anti-PD-1 antibodies) that have demonstrated great promise in oncology.
Targeting viral proteins that have been reported to subvert host immunity is an attractive approach because it alleviates concerns related to "on target" toxicities. Unfortunately, these host-virus interactions have yet to be comprehensively validated in physiologically relevant systems. This illustrates the current challenge for HBV research and development: although many potential new approaches to treat CHB have been identified, therapeutic translation has been challenging and relatively few drug candidates have emerged and entered clinical studies. In the coming years, it is hoped that this trend can be reversed and that major strides can be made in alleviating the global health care burden of HBV.
